Share your videos with the world

As the holiday season approaches and people begin planning their decorations, Cyberonics, Inc. is urging them to maintain the momentum of Epilepsy Awareness Month in November by incorporating purple lights into their holiday décor. To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7378051-cyberonics-launches-mylifeisbright-campaign-healthyandbright-promotion-epilepsy-awareness-month-shine-purple-lights/

Upsher-Smith Laboratories, Inc. [http://www.upsher-smith.com] today announced that its epilepsy-focused educational website, http://www.Epilog.us, has been expanded to include thought-leader commentary on issues related to Epilepsy and Comorbidities. The newly updated website will make its debut at the 64th Annual American Academy of Neurology Meeting in New Orleans on April 23 – 26, 2012, at the Upsher-Smith exhibit, booth number 128. TO view Multimedia News Release, go to http://www.multivu.com/mnr/55934-upsher-smith-expands-epilog-us-on-epilepsy-comorbidities

GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience. To view the multimedia release go to: https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/